Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis

International Journal of Antimicrobial Agents

Volumn 49, Issue 6, 2017, Pages 677-687

  Chang, Min Jung ^a   Jin, Byunghak ^a   Chae, Jung woo ^b   Yun, Hwi yeol ^c   Kim, Eun Sun ^d   Lee, Yeon Joo ^d   Cho, Young Jae ^d   Yoon, Ho Il ^d,e   Lee, Choon Taek ^d,e   Park, Kyoung Un ^d,e   Song, Junghan ^d,e   Lee, Jae Ho ^d,e   Park, Jong Sun ^d  

^a Yonsei University   (South Korea)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Chungnam National University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

Author keywords

Multi drug resistant tuberculosis; Population pharmacokinetics; Second line anti tuberculosis drugs

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ABSORPTION RATE CONSTANT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MIDDLE AGED; MONTE CARLO METHOD; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VOLUME OF DISTRIBUTION; CHEMISTRY; CHROMATOGRAPHY; INTRAMUSCULAR DRUG ADMINISTRATION; PLASMA; STATISTICAL MODEL; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MODELS, STATISTICAL; PLASMA; PROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 85018258618     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.01.024     Document Type: Article

References (27)

1. Zumla, A., George, A., Sharma, V., Herbert, N., Baroness Masham of Ilton. WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet 382 (2013), 1765–1767.
2. Zignol, M., van Gemert, W., Falzon, D., Sismanidis, C., Glaziou, P., Floyd, K., et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 90 (2012), 111–119d.
3. Dobler, C.C., Korver, S., Batbayar, O., Nyamdulam, B., Oyuntsetseg, S., Tsolmon, B., et al. Multidrug-resistant tuberculosis in patients for whom first-line treatment failed, Mongolia, 2010–2011. Emerg Infect Dis 21 (2015), 1451–1454.
4. Prasad, R., Gupta, N., Balasubramanian, V., Singh, A., Multidrug resistant tuberculosis treatment in India. Drug Discov Ther 9 (2015), 156–164.
5. Li, Q., Dong, H.Y., Pang, Y., Xia, H., Ou, X.C., Zhang, Z.Y., et al. Multicenter evaluation of the molecular line probe assay for multidrug resistant Mycobacterium tuberculosis detection in China. Biomed Environ Sci 28 (2015), 464–467.
6. World Health Organization, Management of MDR-TB: a field guide. A companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI). 2009, WHO, Geneva.
7. World Health Organization, Global tuberculosis report 2015. 2015, World Health Organization, Geneva.
8. Falzon, D., Jaramillo, E., Schunemann, H.J., Arentz, M., Bauer, M., Bayona, J., et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38 (2011), 516–528.
9. Dartois, V., Barry, C.E., Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 5 (2010), 96–114.
10. Peloquin, C.A., Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62 (2002), 2169–2183.
11. Alsultan, A., Peloquin, C.A., Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74 (2014), 839–854.
12. de Kock, L., Sy, S.K., Rosenkranz, B., Diacon, A.H., Prescott, K., Hernandez, K.R., et al. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 58 (2014), 6242–6250.
13. Yew, W.W., Cheung, S.W., Chau, C.H., Chan, C.Y., Leung, C.K., Cheng, A.F., et al. Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy. Int J Clin Pharmacol Res 19 (1999), 65–71.
14. Lee, H.W., Kim, D.W., Park, J.H., Kim, S.D., Lim, M.S., Phapale, P.B., et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 13 (2009), 1161–1166.
15. Reynolds, J., Heysell, S.K., Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol 10 (2014), 813–823.
16. Han, M., Jun, S.H., Lee, J.H., Park, K.U., Song, J., Song, S.H., Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. J Antimicrob Chemother 68 (2013), 2066–2073.
17. Blumberg, H.M., Burman, W.J., Chaisson, R.E., Daley, C.L., Etkind, S.C., Friedman, L.N., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167 (2003), 603–662.
18. Pranger, A.D., Kosterink, J.G., van Altena, R., Aarnoutse, R.E., van der Werf, T.S., Uges, D.R., et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 33 (2011), 350–354.
19. Park, S.I., Oh, J., Jang, K., Yoon, J., Moon, S.J., Park, J.S., et al. Pharmacokinetics of second-line antituberculosis drugs after multiple administrations in healthy volunteers. Antimicrob Agents Chemother 59 (2015), 4429–4435.
20. Ito, F., Ohno, Y., Toyoshi, S., Kaito, D., Koumei, Y., Endo, J., et al. Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection. Ther Adv Respir Dis 10 (2016), 34–42.
21. Nijland, H.M., Ruslami, R., Suroto, A.J., Burger, D.M., Alisjahbana, B., van Crevel, R., et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 45 (2007), 1001–1007.
22. Weiner, M., Burman, W., Luo, C.C., Peloquin, C.A., Engle, M., Goldberg, S., et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 51 (2007), 2861–2866.
23. Dooley, K., Flexner, C., Hackman, J., Peloquin, C.A., Nuermberger, E., Chaisson, R.E., et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 52 (2008), 4037–4042.
24. Zhu, M., Nix, D.E., Adam, R.D., Childs, J.M., Peloquin, C.A., Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 21 (2001), 891–897.
25. Donald, P.R., Diacon, A.H., Para-aminosalicylic acid: the return of an old friend. Lancet Infect Dis 15 (2015), 1091–1099.
26. Dijkstra, J.A., van Altena, R., Akkerman, O.W., de Lange, W.C., Proost, J.H., van der Werf, T.S., et al. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. Int J Antimicrob Agents 46 (2015), 332–337.
27. Mahmood, I., Duan, J., Population pharmacokinetics with a very small sample size. Drug Metab Drug Interact 24 (2009), 259–274.